Masoabi Sefojane: In Africa 88% of Hemophilia Remains Undiagnosed
Masoabi Sefojane, Geographic Expansion Lead, Africa and Asia Pacific at MicroHealth , shared a post on LinkedIn:
”The World Federation of Haemophilia identifies 37% of people with haemophilia globally.
In low-income countries? 11%.
In Africa? An estimated 88% remain undiagnosed.
Let me be direct: these numbers represent invisibility by design.
Not because diagnosis is impossible.
But because the systems to find people were built for certain geographies and certain people.
When my brother was 6 years old in Phuthaditjhaba, South Africa, He didn’t exist in any global haemophilia dataset.
He was bleeding, my family was desperate, but he was invisible. No screening protocol would find him.
No registry would record him. No system knew he existed. This could have been my story if it wasn’t for my brothers.
Ask any bleeding disorder patient in the global south and you will hear similar stories and a pattern will also emerge.
Meanwhile, a child born with the same severe haemophilia A in Amsterdam? Known by age 1. Registered. Part of the data that shapes global priorities.
Same disease. Different visibility.
Here’s what the data shows: Africa, with 18% of the world’s population, represents less than 3% of identified haemophilia patients globally.
That’s not because haemophilia is rare in Africa. It’s because the systems designed to find haemophilia were never designed to reach Africa.
The invisibility isn’t accidental. It’s structural.
When a patient is invisible, they don’t exist in clinical trials. They’re not counted in epidemiology.
They don’t influence treatment guidelines. Their outcomes don’t matter because nobody’s measuring them.
The question we need to ask: Are we actually looking for these patients?
Or have we built systems that only find the ones in certain places?
Because that’s the real diagnosis gap.”
Stay updated with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy